As of November 10, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of Evolus, Inc. The largest reported stake is Timothy P. Lynch's, at 9.9%. 12 filings are on record since August 14, 2025 (Schedule 13G/A, February 17, 2026).
Sell to companies like Evolus, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Soleus Capital Master Fund, L.P. · Sole voting: 0 · Shared voting: 5,090,000 · Sole dispositive: 0 · Shared dispositive: 5,090,000 · SCHEDULE 13G/A, 2026-11-09
- · Holder: Soleus Capital Master Fund, L.P. · Percent: 5.3% · SCHEDULE 13G
- · Reporting person: The Vanguard Group · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-03-26
- · Reporting person: Timothy P. Lynch · Sole voting: 4,705,009 · Shared voting: 1,720,717 · Sole dispositive: 4,705,009 · Shared dispositive: 1,720,717 · SCHEDULE 13G/A, 2026-02-17
- · Reporting person: Caligan Partners LP · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-02-17
Evolus, Inc has 12 Schedule 13D or 13G filings on record since 2025-08-14. 3 holders' latest filing reports 5% or more of common stock, par value $0.00001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 9.9% | 6,425,726 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 | |
| Nantahala Capital Management, LLC | 8.85% | 5,726,857 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| Soleus Capital Master Fund, L.P. | 7.7% | 5,090,000 | SCHEDULE 13G/A, 2026-11-09 | 2026-09-30 |
| Perceptive Advisors LLC | 3.8% | 2,474,843 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| Tang Capital Management, LLC | 1.92% | 1,245,692 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| Caligan Partners LP | 0% | 0 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-26 | 2026-03-13 |
Holding shares or following this stake? See who's behind Evolus, Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Evolus, Inc and the records around it.
Evolus, Inc elsewhere on the record
Companies that share a holder
- Timothy P. Lynch also filed stake reports on 1 other company: AEON Biopharma, Inc. (Aug 2026)
- Caligan Partners LP also filed stake reports on 9 other companies: Avalo Therapeutics, Inc. (Aug 2026), Cellectar Biosciences, Inc. (Aug 2026), Faeth Therapeutics, Inc. (Aug 2026)
- Soleus Capital Master Fund, L.P. also filed stake reports on 23 other companies: Processa Pharmaceuticals, Inc. (Aug 2026), CERUS CORP (Aug 2026), IMMUNIC, INC. (Aug 2026)
Watch Evolus, Inc
Get an email when Evolus, Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Evolus, Inc?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Evolus, Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Evolus, Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Timothy P. Lynch | 4,705,009 | 1,720,717 | 4,705,009 | 1,720,717 | SCHEDULE 13G/A, 2026-02-17 |
| Soleus Capital Master Fund, L.P. | 0 | 5,090,000 | 0 | 5,090,000 | SCHEDULE 13G/A, 2026-11-09 |
| Soleus Capital, LLC | 0 | 5,090,000 | 0 | 5,090,000 | SCHEDULE 13G/A, 2026-11-09 |
| Soleus Capital Group, LLC | 0 | 5,090,000 | 0 | 5,090,000 | SCHEDULE 13G/A, 2026-11-09 |
| Soleus Capital Management, L.P. | 0 | 5,090,000 | 0 | 5,090,000 | SCHEDULE 13G/A, 2026-11-09 |
| Soleus GP, LLC | 0 | 5,090,000 | 0 | 5,090,000 | SCHEDULE 13G/A, 2026-11-09 |
| Guy Levy | 0 | 5,090,000 | 0 | 5,090,000 | SCHEDULE 13G/A, 2026-11-09 |
| Caligan Partners LP | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-02-17 |
| David Johnson | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-02-17 |
| The Vanguard Group | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-03-26 |
The latest filing identifies Evolus, Inc by CUSIP 30052C107 and gives its principal executive office as 520 Newport Center Drive, Suite 1200, Newport Beach, CA 92660 (SCHEDULE 13G/A, 2026-11-09).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | Caligan Partners LP | 5.2% | SCHEDULE 13G |
| 2025-08-14 | Perceptive Advisors LLC | 3.8% | SCHEDULE 13G/A |
| 2025-08-18 | Timothy P. Lynch | 6.3% | SCHEDULE 13G |
| 2025-11-14 | Caligan Partners LP | 6.4% | SCHEDULE 13G/A |
| 2025-11-14 | Timothy P. Lynch | 7.9% | SCHEDULE 13G/A |
| 2025-11-14 | Nantahala Capital Management, LLC | 8.85% | SCHEDULE 13G/A |
| 2026-02-17 | Timothy P. Lynch | 9.9% | SCHEDULE 13G/A |
| 2026-02-17 | Tang Capital Management, LLC | 1.92% | SCHEDULE 13G/A |
| 2026-02-17 | Caligan Partners LP | 0% | SCHEDULE 13G/A |
| 2026-03-26 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-08-31 | Soleus Capital Master Fund, L.P. | 5.3% | SCHEDULE 13G |
| 2026-11-09 | Soleus Capital Master Fund, L.P. | 7.7% | SCHEDULE 13G/A |
Questions about who owns Evolus, Inc
Who owns Evolus, Inc?
On this page, 3 holders' latest ownership filings report 5% or more of Evolus, Inc: Timothy P. Lynch (9.9%, Schedule 13G/A, filed 2026-02-17), Nantahala Capital Management, LLC (8.85%, Schedule 13G/A, filed 2025-11-14) and Soleus Capital Master Fund, L.P. (7.7%, Schedule 13G/A, filed 2026-11-09).
Who are the largest shareholders of Evolus, Inc?
By the share each holder's latest filing reports, the largest holders of Evolus, Inc on this page are Timothy P. Lynch (9.9%), Nantahala Capital Management, LLC (8.85%) and Soleus Capital Master Fund, L.P. (7.7%).
When did Timothy P. Lynch buy into Evolus, Inc?
The filings give report dates, not purchase dates. The earliest filing from Timothy P. Lynch on this page is the Schedule 13G, filed 2025-08-18, reporting 6.3%; its latest, Schedule 13G/A filed 2026-02-17, reports 9.9%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Evolus, Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.